Keywords: Britsol-Myers Squibb, Diabetes, Dapagliflozin, AstraZeneca, Zacks, R&D pipeline

Bristol-Myers Squibb’s R&D pipeline boosted by diabetes drug dapagliflozin, say Zacks analysts

Article | 18 October 2010

Print This

US drug major Bristol-Myers Squibb’s (NYSE: BMY) R&D pipeline received a boost when its type 2 diabetes ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in